DNA损伤的修复与胶质瘤对替莫唑胺耐药性的研究进展
作者：张文静;刘倩蓉;张敏;龚文容;秦鑫;
Author：
收稿日期： 年卷（期）页码：2017,32(05):-555-558
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：胶质瘤;替莫唑胺;DNA损伤;修复;O-6-甲基鸟嘌呤-DNA甲基转移酶;错配修复;碱基切除修复;耐药性
Key words：
基金项目：湖北省教育厅科学技术研究项目(Q20162604)
中文摘要
胶质瘤是成人颅内最常见的恶性肿瘤,以手术切除为主,辅以放疗、化疗是目前治疗胶质瘤的主要手段。替莫唑胺(Temozolomide,TMZ)是临床一线胶质瘤化疗药物,但临床使用过程中,胶质瘤对TMZ的耐药影响了化疗效果,限制了其广泛使用。DNA损伤的修复是TMZ耐药的重要机制之一。DNA修复酶与胶质瘤TMZ耐药密切相关,文中对DNA修复酶和胶质瘤TMZ耐药性研究进行了综述。
参考文献
[1]《中国中枢神经系统胶质瘤诊断和治疗指南》编写组.中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J].中华医学杂志,2016(7):485-509.
[2]王计伟,陈步东,张春智,等.替莫唑胺治疗胶质母细胞瘤的长期疗效评价[D].天津:天津医科大学硕士学位论文,2012.
[3]Stupp R,Mason WP,Van Den Bent MJ,et al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J].N Engl J Med,2005,352(10):987-996.
[4]Kaina B,Christmann M,Naumann S,et al.MGMT:Key node in the battle against genotoxicity,carcinogenicity and apoptosis induced by alkylating agents[J].DNA Repair(Amst),2007,6(8):1079-1099.
[5]Hegi ME,Diserens AC,Gorlia T,et al.MGMT gene silencing and benefit from Temozolomide in glioblastoma[J].N Engl J Med,2005,352(10):997-1003.
[6]Hegi ME,Liu L,Herman JG,et al.Correlation of O6-methylguanine methyltransferase(MGMT)promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity[J].J Clin Oncol,2008,26(25):4189-4199.
[7]Viel T,Monfared P,Schelhaas S,et al.Optimizing glioblastoma Temozolomide chemotherapy employing lentiviral-based antiMGMT shRNA technology[J].Mol Ther,2013,21(3):570-579.
[8]Weller M,Tabatabai G,Kastner B,et al.MGMT promoter methylation is a strong prognostic biomarker for benefit from doseintensified temozolomide rechallenge in progressive glioblastoma:The director trial[J].Clin Cancer Res,2015,21(9):2057-2064.
[9]Esteller M,Garcia-Foncillas J,Andion E,et al.Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents[J].N Engl J Med,2000,343(19):1350-1354.
[10]Grombacher T,Eichhorn U,Kaina B.p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase(MGMT)by DNA damaging agents[J].Oncogene,1998,17(7):845-851.
[11]Natsume A,Wakabayashi T,Ishii D,et al.A combination of IFN-beta and Temozolomide in human glioma xenograft models:Implication of p53-mediated MGMT downregulation[J].Cancer Chemother Pharmacol,2008,61(4):653-659.
[12]Novakova J,Slaby O,Vyzula R,et al.MicroRNA involvement in glioblastoma pathogenesis[J].Biochem Biophys Res Commun,2009,386(1):1-5.
[13]Zhang W,Zhang J,Hoadley K,et al.miR-181d:A predictive glioblastoma biomarker that downregulates MGMT expression[J].Neuro Oncol,2012,14(6):712-719.
[14]Kushwaha D,Ramakrishnan V,NG K,et al.A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas[J].Oncotarget,2014,5(12):4026-4039.
[15]Quintavalle C,Mangani D,Roscigno G,et al.MiR-221/222target the DNA methyltransferase MGMT in glioma cells[J].PLo S One,2013,8(9):e74466.
[16]Ogura R,Tsukamoto Y,Natsumeda M,et al.Immunohistochemical profiles of IDH1,MGMT and P53:Practical significance for prognostication of patients with diffuse gliomas[J].Neuropathology,2015,35(4):324-335.
[17]Minniti G,Scaringi C,Arcella A,et al.IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy[J].J Neurooncol,2014,118(2):377-383.
[18]Quinn JA,Jiang SX,Reardon DA,et al.Phase II trial of Temozolomide plus O6-benzylguanine in adults with recurrent,Temozolomide-resistant malignant glioma[J].J Clin Oncol,2009,27(8):1262-1267.
[19]Warren KE,Gururangan S,Geyer JR,et al.A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas:A pediatric brain tumor consortium study[J].J Neurooncol,2012,106(3):643-649.
[20]Taspinar M,Ilgaz S,Ozdemir M,et al.Effect of lomeguatribTemozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells[J].Tumour Biol,2013,34(3):1935-1947.
[21]Drablos F,Feyzi E,AAS PA,et al.Alkylation damage in DNA and RNA-repair mechanisms and medical significance[J].DNA Repair(Amst),2004,3(11):1389-1407.
[22]毕利军,周亚凤,邓教宇,等.DNA错配修复系统研究进展[J].生物化学与生物物理进展,2003,30(1):32-37.
[23]Zhang J,Stevens MF,Bradshaw TD.Temozolomide:Mechanisms of action,repair and resistance[J].Curr Mol Pharmacol,2012,5(1):102-114.
[24]Felsberg J,Thon N,Eigenbrod S,et al.Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1,MSH2,MSH6 and PMS2 in paired primary and recurrent glioblastomas[J].Int J Cancer,2011,129(3):659-670.
[25]Von Bueren AO,Bacolod MD,Hagel C,et al.Mismatch repair deficiency:A Temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours[J].Br J Cancer,2012,107(8):1399-1408.
[26]Shinsato Y,Furukawa T,Yunoue S,et al.Reduction of MLH1and PMS2 confers Temozolomide resistance and is associated with recurrence of glioblastoma[J].Oncotarget,2013,4(12):2261-2270.
[27]Tentori L,Graziani G.Recent approaches to improve the antitumor efficacy of Temozolomide[J].Curr Med Chem,2009,16(2):245-257.
[28]况里杉,王宇亮,周向东.碱基切除修复与抗肿瘤药物耐药[J].肿瘤,2013,33(3):294-298.
[29]Kinsella TJ.Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers[J].Clin Cancer Res,2009,15(6):1853-1859.
[30]Montaldi AP,Sakamoto-Hojo ET.Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide[J].Clin Exp Med,2013,13(4):279-288.
[31]Montaldi AP,Godoy PR,Sakamoto-Hojo ET.APE1/REF-1down-regulation enhances the cytotoxic effects of Temozolomide in a resistant glioblastoma cell line[J].Mutat Res Genet Toxicol Environ Mutagen,2015,793:19-29.
[32]Goellner EM,Grimme B,Brown AR,et al.Overcoming Temozolomide resistance in glioblastoma via dual inhibition of NAD+biosynthesis and base excision repair[J].Cancer Res,2011,71(6):2308-2317.
[33]Tang JB,Svilar D,Trivedi RN,et al.N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide[J].Neuro Oncol,2011,13(5):471-486.
【关闭】
